Affymetrix's Q3 Revenues Down 5 Percent on Service Business Decline | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – A $5 million decline in service revenues was one of the reasons for a 5 percent drop in total revenues for Affymetrix during its third quarter, the company reported Wednesday after the close of the market.

For the three months ended Sept. 30, the Santa Clara, Calif.-based microarray firm reported total revenues of $74 million, down from $78.2 million a year ago, but still above analyst estimates of $73.3 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.